story of the week
CDK4/6 Inhibitor Outcomes in Patients With Advanced Breast Cancer With Germline Pathogenic Variants in DNA Repair–Related Genes
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
JCO Precision Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Cyclin-Dependent Kinase 4/6 Inhibitor Outcomes in Patients With Advanced Breast Cancer Carrying Germline Pathogenic Variants in DNA Repair-Related Genes
JCO Precis Oncol 2022 Mar 01;6(2022)e2100140, L Bruno, A Ostinelli, F Waisberg, D Enrico, C Ponce, S Rivero, A Blanco, M Zarba, M Loza, V Fabiano, M Amat, MT Pombo, L Noro, M Chacón, F Coló, R Chacón, J Nadal, A Nervo, V CostanzoFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.